A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia

Min-Soo Lee, Yong Ku Kim, Sang Kyu Lee, Kwang Yoon Suh

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol. In addition to their haloperidol regimen, 36 inpatients with chronic schizophrenia were randomly assigned to receive capsulized sertraline (50 mg/day; N = 18) or identically capsulized placebo (N = 18) for 8 weeks. The results from the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) Scale, Simpson-Angus Extrapyramidal Effects (S-A) Scale, and plasma concentration levels of haloperidol and reduced haloperidol were examined at baseline and 2, 4, 6, and 8 weeks of treatment. No significant differences between the three PANSS factors (positive, negative, general psychopathology) scores, CGI Scale scores, or S-A Scale scores were recorded at any point during sertraline and placebo treatment. Neither plasma haloperidol or reduced haloperidol concentrations was changed significantly at any point during the sertraline and placebo treatments. In this study, the addition of sertraline 50 mg to the treatment regimen of inpatients did not differ significantly from the placebo effect on positive and negative symptoms and extrapyramidal side effects. The results further indicate that the pharmacokinetics of haloperidol are seemingly unaffected by sertraline.

Original languageEnglish
Pages (from-to)399-403
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume18
Issue number5
DOIs
Publication statusPublished - 1998 Oct 1

Fingerprint

Sertraline
Haloperidol
Double-Blind Method
Schizophrenia
Placebos
Inpatients
Pharmacokinetics
Therapeutics
Placebo Effect
Psychopathology

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. / Lee, Min-Soo; Kim, Yong Ku; Lee, Sang Kyu; Suh, Kwang Yoon.

In: Journal of Clinical Psychopharmacology, Vol. 18, No. 5, 01.10.1998, p. 399-403.

Research output: Contribution to journalArticle

@article{ae8d1d4bee694037888a0c3a9841d73a,
title = "A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia",
abstract = "We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol. In addition to their haloperidol regimen, 36 inpatients with chronic schizophrenia were randomly assigned to receive capsulized sertraline (50 mg/day; N = 18) or identically capsulized placebo (N = 18) for 8 weeks. The results from the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) Scale, Simpson-Angus Extrapyramidal Effects (S-A) Scale, and plasma concentration levels of haloperidol and reduced haloperidol were examined at baseline and 2, 4, 6, and 8 weeks of treatment. No significant differences between the three PANSS factors (positive, negative, general psychopathology) scores, CGI Scale scores, or S-A Scale scores were recorded at any point during sertraline and placebo treatment. Neither plasma haloperidol or reduced haloperidol concentrations was changed significantly at any point during the sertraline and placebo treatments. In this study, the addition of sertraline 50 mg to the treatment regimen of inpatients did not differ significantly from the placebo effect on positive and negative symptoms and extrapyramidal side effects. The results further indicate that the pharmacokinetics of haloperidol are seemingly unaffected by sertraline.",
author = "Min-Soo Lee and Kim, {Yong Ku} and Lee, {Sang Kyu} and Suh, {Kwang Yoon}",
year = "1998",
month = "10",
day = "1",
doi = "10.1097/00004714-199810000-00008",
language = "English",
volume = "18",
pages = "399--403",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia

AU - Lee, Min-Soo

AU - Kim, Yong Ku

AU - Lee, Sang Kyu

AU - Suh, Kwang Yoon

PY - 1998/10/1

Y1 - 1998/10/1

N2 - We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol. In addition to their haloperidol regimen, 36 inpatients with chronic schizophrenia were randomly assigned to receive capsulized sertraline (50 mg/day; N = 18) or identically capsulized placebo (N = 18) for 8 weeks. The results from the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) Scale, Simpson-Angus Extrapyramidal Effects (S-A) Scale, and plasma concentration levels of haloperidol and reduced haloperidol were examined at baseline and 2, 4, 6, and 8 weeks of treatment. No significant differences between the three PANSS factors (positive, negative, general psychopathology) scores, CGI Scale scores, or S-A Scale scores were recorded at any point during sertraline and placebo treatment. Neither plasma haloperidol or reduced haloperidol concentrations was changed significantly at any point during the sertraline and placebo treatments. In this study, the addition of sertraline 50 mg to the treatment regimen of inpatients did not differ significantly from the placebo effect on positive and negative symptoms and extrapyramidal side effects. The results further indicate that the pharmacokinetics of haloperidol are seemingly unaffected by sertraline.

AB - We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol. In addition to their haloperidol regimen, 36 inpatients with chronic schizophrenia were randomly assigned to receive capsulized sertraline (50 mg/day; N = 18) or identically capsulized placebo (N = 18) for 8 weeks. The results from the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) Scale, Simpson-Angus Extrapyramidal Effects (S-A) Scale, and plasma concentration levels of haloperidol and reduced haloperidol were examined at baseline and 2, 4, 6, and 8 weeks of treatment. No significant differences between the three PANSS factors (positive, negative, general psychopathology) scores, CGI Scale scores, or S-A Scale scores were recorded at any point during sertraline and placebo treatment. Neither plasma haloperidol or reduced haloperidol concentrations was changed significantly at any point during the sertraline and placebo treatments. In this study, the addition of sertraline 50 mg to the treatment regimen of inpatients did not differ significantly from the placebo effect on positive and negative symptoms and extrapyramidal side effects. The results further indicate that the pharmacokinetics of haloperidol are seemingly unaffected by sertraline.

UR - http://www.scopus.com/inward/record.url?scp=0008762402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0008762402&partnerID=8YFLogxK

U2 - 10.1097/00004714-199810000-00008

DO - 10.1097/00004714-199810000-00008

M3 - Article

VL - 18

SP - 399

EP - 403

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -